Esketamine nasal spray (ESK) is indicated, in conjunction with an oral antidepressant
(OAD), for the management of treatment-resistant depression (TRD) in adults. Select US …

Ketamine was initially used as an anesthetic which could induce cognitive impairment and
psychomimetic effects. In initial randomized controlled trials (RCTs) that mostly included a …

Background: Several recent trials indicate low-dose ketamine produces rapid
antidepressant effects. However, uncertainty remains in several areas: dose response …

Background While ketamine has been increasingly studied for treatment resistant
depression (TRD), the impact of sex differences on treatment outcomes has not been well …

Objectives Rigorous clinical trials suggest ketamine is safe and well-tolerated in patients
with treatment-resistant depression (TRD). There is a paucity of data on the safety and …

Background Ketamine has recently gained prominence as one of the most effective
therapeutic options in unipolar treatment-resistant depression (TRD). However, most studies …

Purpose The aim of the study was to assess the effectiveness, tolerability, and safety of oral
ketamine as an antidepressant treatment in adults with treatment-resistant depression …

Purpose: Approximately 30% of patients with major depressive disorder (MDD) are
treatment resistant. There is an unquestionable need for new treatment strategies …

Background Ketamine has emerged as a fast-acting and powerful antidepressant, but no
head to head trial has been performed, Here, ketamine is compared with electroconvulsive …

About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …